DSpace Repository

Pathophysiological and clinical significance of anti-nuclear antibodies in systemic sclerosis

Show simple item record

dc.contributor.author Zaripov S.I.
dc.date.accessioned 2023-11-26T15:19:19Z
dc.date.available 2023-11-26T15:19:19Z
dc.date.issued 2023
dc.identifier.citation Toshkent en_US
dc.identifier.issn 2181-3183
dc.identifier.uri http://repository.tma.uz/xmlui/handle/1/9416
dc.description.abstract Systemic sclerosis (M34.0) is a polysyndromic autoimmune disease characterized by progressive fibrosis of the skin, musculoskeletal system, internal organs (lungs, kidneys, heart, digestive system) and vasospastic disturbances.It occurs in around 30 people per million population per year and there are an estimated 125,000 active cases in the United States and perhaps 2.5 million worldwide. Although systemic sclerosis is infrequent, it has a high morbidity and mortality and serious life threatening complications. The main marker of an abnormal immune response is circulating autoantibodies, which are found in more than 95% of patients with systemic sclerosis. It is important to study the clinical, immunological, diagnostic and prognostic significance of autoantibodies. en_US
dc.language.iso en en_US
dc.relation.ispartofseries УДК;616.12-008.46-06:616.12-008.331.1- 616.5-004.1
dc.subject Systemic sclerosis, anti-nuclear antibodies, fibrillarin-(U3-RNP), AFA- anti-fibrillarin antibodies, Raynaud's phenomenon en_US
dc.title Pathophysiological and clinical significance of anti-nuclear antibodies in systemic sclerosis en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account